Under an agreement with a leading European sensor developer, Zenosense is developing a device intended for the detection of the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug”, commonly known as the staph infection. Zenosense has exclusive global licensing rights for the sensory device, which is being designed for use in hospitals and other healthcare settings.
Under its development and exclusive global licensing agreement, Zenosense also has rights to development and marketing of sensory devices that can detect certain types of cancer within their early stages. The company notes that there is a strong need for an early-stage cancer detection device. It believes that the sensory technology and algorithmic processing it is currently developing could be adapted for early detection of cancers such as lung cancer and colon cancer.
At present, lung cancer is typically identified at a stage of development in which fewer than 25 percent of cases are curable. However, when it is detected at stage-one, there is a cure rate of over 70 percent. The development of a device with these capabilities would have tremendous implications for improved patient survival rates of lung and colon cancer, and subsequently substantial impacts on the healthcare delivery costs usually associated with cancer healthcare service-providing.
Currently, Zenosense’s sensor developer partner, the Sgenia Group, is working on pioneering rapid, low-cost detection measures for the staph infection. Zenosense intends to deploy this potentially cutting-edge sensory technology to healthcare settings for alleviating healthcare-associated infections and their heavy-handed influence on medical service costs. In the United States alone, it is estimated that between $3.2 billion and $4.2 billion is spent per year on treatment of hospitalized staph-infected patients. Patients who have contracted MRSA are reported to be likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Utilizing specialized hardware and state-of-the-art “sniffer” technology, the medical device is expected to function as a medical “smoke detector” and identify any presence of MRSA in a healthcare setting or infected patient before the presence of MRSA is more noticeable. With its electronic nose, the device would have the technological potency of tens of thousands of “virtual sensors” wrapped into a single, high-performance sensory capability.
Once it is finally developed, the detection device will be capable of being worn by patients as well as deployed to critical locations within hospital settings. Recent studies confirm the tremendous potential for Zenosense’s medical device: implementation of such preventative practices could reduce certain HAIs by up to 70 percent.
For more information about Zenosense, please visit: www.zenosense.net
Let us hear your thoughts: Zenosense, Inc. Message Board